Business Description
Cormedix Inc
NAICS : 325412
SIC : 2834
ISIN : US21900C1009
Description
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets.
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 92.65 | |||||
Equity-to-Asset | 0.85 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.01 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 1.4 | |||||
3-Year EPS without NRI Growth Rate | -5.8 | |||||
3-Year FCF Growth Rate | 0.5 | |||||
3-Year Book Growth Rate | -1 |
Momentum Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 31.17 | |||||
9-Day RSI | 29.94 | |||||
14-Day RSI | 31.39 | |||||
6-1 Month Momentum % | 52.26 | |||||
12-1 Month Momentum % | 43.03 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 6.65 | |||||
Quick Ratio | 6.41 | |||||
Cash Ratio | 6.14 | |||||
Days Inventory | 986.26 | |||||
Days Payable | 1233.6 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -17.9 | |||||
Shareholder Yield % | -21.42 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -79.91 | |||||
ROA % | -70.21 | |||||
ROIC % | -1750.69 | |||||
ROC (Joel Greenblatt) % | -2161.22 | |||||
ROCE % | -81.35 |
GF Value Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 3.9 | |||||
Price-to-Tangible-Book | 4.04 | |||||
EV-to-EBIT | -3.27 | |||||
EV-to-EBITDA | -3.27 | |||||
EV-to-Forward-Revenue | 3.64 | |||||
EV-to-FCF | -3.69 | |||||
Price-to-Net-Current-Asset-Value | 4.25 | |||||
Price-to-Net-Cash | 4.68 | |||||
Earnings Yield (Greenblatt) % | -30.58 | |||||
FCF Yield % | -20.18 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Cormedix Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | |||
EPS (TTM) (€) | -0.858 | ||
Beta | 2.15 | ||
Volatility % | 51.9 | ||
14-Day RSI | 31.39 | ||
14-Day ATR (€) | 0.088306 | ||
20-Day SMA (€) | 4.057 | ||
12-1 Month Momentum % | 43.03 | ||
52-Week Range (€) | 2.66 - 5.85 | ||
Shares Outstanding (Mil) | 54.96 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Cormedix Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Cormedix Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Cormedix Inc Frequently Asked Questions
What is Cormedix Inc(FRA:19KA)'s stock price today?
The current price of FRA:19KA is €3.70. The 52 week high of FRA:19KA is €5.85 and 52 week low is €2.66.
When is next earnings date of Cormedix Inc(FRA:19KA)?
The next earnings date of Cormedix Inc(FRA:19KA) is 2024-08-08 Est..
Does Cormedix Inc(FRA:19KA) pay dividends? If so, how much?
Cormedix Inc(FRA:19KA) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |